Penumbra, Inc. (PEN)

Market Cap	12.65B +9.0%
Revenue (ttm)	1.45B +17.3%
Net Income	171.05M +305.0%
EPS	4.34 +302.4%
Shares Out	39.33M
PE Ratio	74.16
Forward PE	60.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	351,888
Open	321.88
Previous Close	322.23
Day's Range	321.38 - 323.07
52-Week Range	221.26 - 362.41
Beta	0.74
Analysts	Hold
Price Target	356.64 (+10.86%)
Earnings Date	May 6, 2026

About PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 4,700
• Stock Exchange: NYSE
• Ticker Symbol: PEN
• Website: https://www.penumbrainc.com

Financial Performance

In 2025, Penumbra's revenue was $1.40 billion, an increase of 17.50% compared to the previous year's $1.19 billion. Earnings were $177.69 million, an increase of 1168.11%.

Analyst Summary

According to 16 analysts, the average rating for PEN stock is "Hold." The 12-month stock price target is $356.64, which is an increase of 10.86% from the latest price.

Price Target

$356.64

(10.86% upside)

Analyst Consensus: Hold